Injective stalls below $7.6 resistance with consolidation likely amid mixed indicators: weekly analysis
Injective (INJ) has pulled back to around $7.31 after a sharp decline of more than 9% over the past week, with bears appearing to exhaust their momentum as key support comes into focus. The technical picture signals deeply oversold conditions, but with mixed indicators, the outlook for a rebound remains uncertain. Traders are watching to see whether sellers can drive the price lower or if a technical bounce is in store.
Highlights
- Injective fell 9.15% over 7 days to $7.31, trading below short-term averages but above long-term support.
- Short-term technicals show oversold conditions and mixed momentum, with a MACD Sell signal despite potential for a rebound.
- Price is expected to consolidate between $6.56 and $7.6, with a 67% probability of further decline and a projected range of $6.31 to $8.3 for the next week.
Community upgrades boost sentiment as Veyra voting and buybacks advance
Injective has opened governance voting on the Veyra mainnet upgrade, which is designed to expand institutional trading and bring new tokenized asset markets, according to Altcoin Buzz. The proposal has already surpassed the required quorum, with over 99% of stakers approving the changes, as reported by Bloomingbit, paving the way for new infrastructure and privacy enhancements. Additional developments include the November Community BuyBack event involving over $164,000 worth of INJ to be burned, and Injective's affiliate achieving SEC registration as a transfer agent (sources: Cryptonews.net, The Defiant).
Mixed technical signals persist as volatility and oversold oscillators guide moves
On the daily chart, price action is defined by a sharp move lower without a sustained trend and volatility at 28.66%. Both the CCI and the Stochastic RSI register oversold, suggesting selling exhaustion and highlighting potential for a technical rebound. MACD provides a Sell signal, while oscillators otherwise indicate neutral momentum, showing mixed intraday sentiment. Price is capped by resistance at $7.6 from both the 20-day average and the Ichimoku Kijun, while $6.56 offers the closest support.
Continued consolidation expected as downside risk outweighs recovery chances
For the next 7 days, the expected range is $6.31 to $8.3 and the probability of a decrease stands at 67%, with only a 33% chance of recovery. The base case is further consolidation between $6.56 and $7.6, with temporary bounces likely if the oversold momentum persists. A sustained move above $7.6 could open the way for a push toward $8.3, while loss of support below $6.56 would expose downside risk toward $6.31.
Earlier, analysts noted that Injective was demonstrating sustained bullish momentum, supported by protocol upgrades and institutional activity. The latest developments and price action introduce uncertainty and highlight the importance of monitoring $6.56 as a key support level, with consolidation likely to persist unless a decisive move shifts the current balance.